<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; bias</title>
	<atom:link href="http://www.tapanray.in/tag/bias/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
